Synonyms: BAY-3427080 | BAY3427080 | Compound A [WO2021094247A1] | Example 34 [WO2007028654A1] | NT-814 | NT814
Compound class:
Synthetic organic
|
|
No information available. |
Summary of Clinical Use |
Elinzanetant (BAY3427080)was progressed to clinical studies to evaluate its potential to treat vasomotor symptoms of the menopause (hot flushes/flashes, night sweats). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03596762 | A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms | Phase 2 Interventional | Bayer | The SWITCH-1 study. Positive results (decrease in VMS in postmenopausal women) were published in March 2023. | 3 |
NCT02865538 | Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms | Phase 1/Phase 2 Interventional | Bayer | The RELENT-1 study. | 4 |